JCAD, a new potential therapeutic target in cholestatic liver disease.
作者信息
Jang Byoung Kuk
机构信息
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
出版信息
Clin Mol Hepatol. 2024 Apr;30(2):166-167. doi: 10.3350/cmh.2024.0128. Epub 2024 Mar 8.
Abstract
摘要
相似文献
1
JCAD, a new potential therapeutic target in cholestatic liver disease.JCAD，胆汁淤积性肝病中一个新的潜在治疗靶点。
Clin Mol Hepatol. 2024 Apr;30(2):166-167. doi: 10.3350/cmh.2024.0128. Epub 2024 Mar 8.
2
Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.胆管细胞来源的外泌体长链非编码 RNA H19 促进肝星状细胞激活和胆汁淤积性肝纤维化。
Hepatology. 2019 Oct;70(4):1317-1335. doi: 10.1002/hep.30662. Epub 2019 May 24.
3
Vitamin A deficiency in chronic cholestatic liver disease: Is vitamin A therapy beneficial?慢性胆汁淤积性肝病中的维生素 A 缺乏：维生素 A 治疗是否有益？
Liver Int. 2017 Dec;37(12):1752-1758. doi: 10.1111/liv.13433. Epub 2017 Jul 29.
4
Endothelin-1 aggravates hepatic ischemia/reperfusion injury during obstructive cholestasis in bile duct ligated mice.内皮素-1 在胆管结扎小鼠阻塞性胆汁淤积时加重肝缺血/再灌注损伤。
J Surg Res. 2010 Jul;162(1):46-53. doi: 10.1016/j.jss.2007.07.024.
5
Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.阻断 BAFF 重塑胆汁淤积性肝病中的肝 B 细胞受体库并减轻自身抗体产生。
J Immunol. 2020 Jun 15;204(12):3117-3128. doi: 10.4049/jimmunol.1900391. Epub 2020 Apr 24.
6
P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.P4HA2 诱导慢性胆汁淤积性肝病中的胆管反应和胆汁性纤维化。
Hepatology. 2023 Jul 1;78(1):10-25. doi: 10.1097/HEP.0000000000000317. Epub 2023 Feb 20.
7
Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice.敲除微小RNA-21可减轻胆管结扎诱导的胆汁淤积性小鼠的胆管增生和肝纤维化。
Lab Invest. 2016 Dec;96(12):1256-1267. doi: 10.1038/labinvest.2016.112. Epub 2016 Oct 24.
8
Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis.bcl-2在小胆管增生中的表达与自身免疫性胆汁淤积患者的汇管区肝星状细胞活化及纤维化进展相关。
Dig Liver Dis. 2007 Mar;39(3):262-6. doi: 10.1016/j.dld.2006.12.004. Epub 2007 Jan 30.
9
Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.叉头框A2调节小鼠胆汁淤积性肝损伤期间的胆管异质性和衰老‡
Hepatology. 2017 Feb;65(2):544-559. doi: 10.1002/hep.28831. Epub 2016 Nov 5.
10
Slit2 signaling contributes to cholestatic fibrosis in mice by activation of hepatic stellate cells.Slit2 信号通过激活肝星状细胞促进小鼠胆汁淤积性纤维化。
Exp Cell Res. 2019 Dec 1;385(1):111626. doi: 10.1016/j.yexcr.2019.111626. Epub 2019 Sep 20.
引用本文的文献
1
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances.在各种情况下，肝实质细胞和非实质细胞均表达JCAD蛋白。
Clin Mol Hepatol. 2024 Apr;30(2):279-280. doi: 10.3350/cmh.2024.0191. Epub 2024 Mar 20.
本文引用的文献
1
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.JCAD 缺乏可减弱肝星状细胞的活化和胆汁淤积性纤维化。
Clin Mol Hepatol. 2024 Apr;30(2):206-224. doi: 10.3350/cmh.2023.0506. Epub 2024 Jan 8.
2
Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.原发性胆汁性胆管炎：天然产物的分子发病机制研究进展与治疗潜力。
Front Immunol. 2023 Jun 30;14:1164202. doi: 10.3389/fimmu.2023.1164202. eCollection 2023.
3
Epidemiology and updated management for autoimmune liver disease.自身免疫性肝病的流行病学及最新管理
Clin Mol Hepatol. 2023 Jan;29(1):194-196. doi: 10.3350/cmh.2022.0387. Epub 2022 Dec 14.
4
JCAD: a new GWAS target to reduce residual cardiovascular risk?《美国心脏病学会杂志》：降低心血管残余风险的新全基因组关联研究靶点？
Eur Heart J. 2023 May 21;44(20):1834-1836. doi: 10.1093/eurheartj/ehac708.
5
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?机制与分子：原发性胆汁性胆管炎的治疗靶点是什么？
Hepatology. 2022 Aug;76(2):518-531. doi: 10.1002/hep.32405. Epub 2022 Mar 10.
6
Current understanding of primary biliary cholangitis.原发性胆汁性胆管炎的现有认识。
Clin Mol Hepatol. 2021 Jan;27(1):1-21. doi: 10.3350/cmh.2020.0028. Epub 2020 Dec 3.
7
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.原发性胆汁性胆管炎：美国肝病研究协会2018年实践指南
Hepatology. 2019 Jan;69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6.
8
JCAD, a Gene at the 10p11 Coronary Artery Disease Locus, Regulates Hippo Signaling in Endothelial Cells.JCAD，位于 10p11 号染色体的冠状动脉疾病区域的一个基因，调控内皮细胞中的 Hippo 信号通路。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1711-1722. doi: 10.1161/ATVBAHA.118.310976.
9
JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.JCAD 通过抑制 LATS2 激酶活性促进非酒精性脂肪性肝炎向肝癌的进展。
Cancer Res. 2017 Oct 1;77(19):5287-5300. doi: 10.1158/0008-5472.CAN-17-0229. Epub 2017 Aug 3.
10
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.EASL 临床实践指南：原发性胆汁性胆管炎患者的诊断和管理。
J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18.
Zotero 插件